Correlation between platelet and brain PLA2 activity

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 4, 2013, Pages 265-268

  Talib, Leda L ^a   Valente, Kette D ^a   Vincentiis, Silvia ^a   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brain tissue; Epilepsy; Hippocampus; Neuropsychiatric disorders; PLA2; Platelets; Radioenzymatic assays

Indexed keywords

ANTICONVULSIVE AGENT; PHOSPHOLIPASE A2;

ADULT; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HIPPOCAMPAL SCLEROSIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHOSIS; RADIOIMMUNOASSAY; TEMPORAL LOBE EPILEPSY; TEMPORAL LOBECTOMY; THROMBOCYTE;

BRAIN TISSUE; EPILEPSY; HIPPOCAMPUS; NEUROPSYCHIATRIC DISORDERS; PLA(2); PLATELETS; RADIOENZYMATIC ASSAYS;

ADULT; ANTERIOR TEMPORAL LOBECTOMY; BLOOD PLATELETS; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; YOUNG ADULT;

EID: 84884534630     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.07.002     Document Type: Article

References (33)

1. Piomelli D. Arachidonic acid in cell signaling. Curr. Opin. Cell. Biol. 1993, 5:274-280.
2. Bazan N.G., Zorumski C.F., Clark G.D. The activation of phospholipase A2 and release of arachidonic acid and other lipid mediators at the synapse: the role of platelet activating factor. J. Lipid. Mediat. 1993, 6:421-427.
3. Gattaz W.F., Köllisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptics therapy. Biol. Psychiatry. 1987, 22:421-426.
4. Gattaz W.F., Hübner C.K., Nevalainen T.J., Thuren T., Kinnunen P.K.J. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 1990, 28:495-501.
5. Gattaz W.F., Steudle A., Maras A. Increased platelet phospholipase A2 in schizophrenia. Schizophr. Res. 1995, 16:1-6.
6. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., Wolkin A., Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 1993, 34:641-649.
7. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Arch. Gen. Psychiatry. 1997, 54:487-494.
8. Ross B.M., Turenne S., Moszczynska A., Warsh J.J., Kish S.J. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain. Res. 1999, 821:407-413.
9. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000, 42:7-17.
10. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 2002, 61:1-6.
11. Gattaz W.F., Maras A., Cairns N.J., Levy R., Förstl H. Decresed phospholipase A2 activity in Alzheimer brain. Biol. Psychiatry. 1995, 37:13-17.
12. Gattaz W.F., Cairns N.J., Levy R., Förstl H., Braus D.F., Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246:129-131.
13. Gattaz W.F., Forlenza O.V., Talib L.L., Barbosa N.R., Bottino C.M. Platelet phospholipase A(2) activity in Alzheimer's disease and mild cognitive impairment. J. Neural. Transm. 2004, 111:591-601.
14. (+2)-sensitive cytosolic phospholipase A2 in human platelets. J Biol Chem 1993, 268:26796-26804.
15. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression focus on the serotonim transporter. Clin. Chem 1994, 40:288-295.
16. Zainaghi I.A., Forlenza O.V., Gattaz W.F. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology. (Berl). 2007, 192:547-553.
17. Commission on classification and terminology of the international league against epilepsy (ILAE) proposal for classification of epilepsy and epileptic syndromes, Epilepsia 30 (1989) pp. 389-399.
18. Gattaz W.F., Valente K.D., Raposo N.R., Vincentiis S., Talib L.L. Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. J. Psychiatr. Res. 2011, 45:1617-1620.
19. Wen H.T., Rhoton A.L., de Oliveira E., Cardoso A.C., Tedeschi H., Baccanelli M., et al. Microsurgical anatomy of the temporal lobe: part 1: mesial temporal lobe anatomy and its vascular relationships as applied to amygdalohippocampectomy. Neurosurgery 1999, 45:549-591.
20. Wen H.T., Rhoton A.L., Marino R. Gray matter overlying anterior basal temporal sulci as an intraoperative landmark for locating the temporal horn in amygdalohippocampectomies. Neurosurgery 2006, 59.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin-phenol reagents. J Biol Chem 1951, 193:265-275.
22. Talib L.L., Diniz B.S., Zainaghi I.A., Forlenza O.V., Gattaz W.F. A radioenzymatic assay to identify three groups of phospholipase A(2) in platelets. Prostaglandins. Leukot. Essent. Fatty. Acids. 2012, 86:149-153.
23. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem 2001, 77:796-803.
24. Bosetti F., Weerasinghe G.R., Rosenberger T.A., Rapoport S.I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem 2003, 85(3):690-696.
25. Farooqui A.A., Ong W.Y., Horrocks L.A. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 2006, 58:591-620.
26. Trzeciak H.I., Kalacinski W., Malecki A., Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur. Arch. Psychiatry. Clin. Neurosci. 1995, 245:179-182.
27. Gattaz W.F., Köllisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase A2 actyvity in schizophrenic patients: reduction after neuroleptics therapy. Biol. Psychiatry. 1987, 22:421-426.
28. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 2003, 61:1-6.
29. Schmitt A., Maras A., Petroianu G., Braus D.F., Scheuer L., Gattaz W.F. Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia. J. Neural. Transm. 2001, 108:1081-1091.
30. Smesny S., Kinder D., Willhardt I., Rosburg T., Lasch J., Berger G., et al. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol. Psychiatry. 2005, 57:399-405.
31. Smesny S., Milleit B., Nenadic I., Preul C., Kinder D., Lasch J., et al. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. Neuroimage 2010, 52:1314-1327.
32. Barradas M.A., Mikhailidis D.P. The use of platelets as models for neurons: possible applications to the investigation of eating disorders. Biomed. Pharmacother. 1993, 47:11-18.
33. Haouari M., Rosado J.A. Platelet function in hypertension. Blood. Cells. Mol. Dis. 2009, 42:38-43.